Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Neximmune Inc NEXI

Healthcare Biotechnology
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (PINL:NEXI)

NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire February 6, 2024

NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire February 2, 2024

NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes

GlobeNewswire October 24, 2023

NexImmune Announces Presentations at The Society for Immunotherapy of Cancer's 38th Annual Meeting

GlobeNewswire October 19, 2023

NexImmune Announces 1-for-25 Reverse Stock Split

GlobeNewswire October 18, 2023

NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy

GlobeNewswire August 31, 2023

NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates

GlobeNewswire August 10, 2023

NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting

GlobeNewswire June 5, 2023

NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting

GlobeNewswire May 22, 2023
View More News ››

Opinion & Analysis (PINL:NEXI)

No current opinion is available.
View More Opinion ››

Bullboard Posts (PINL:NEXI)

NexImmune, Inc. (NASDAQ:NEXI): A Promising Biotech Poised fo

http://beyondspx.com/2024/08/03/neximmune-inc-nasdaqnexi-a-promising-biotech-poised-for-transformation/
MikeTester - August 3, 2024

NexImmune Announces Closing of $3.67 Million Registered Dire

BREAKING NEWS: $NEXI NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq...
whytestocks - February 6, 2024

NexImmune Announces $3.67 Million Registered Direct Offering

Just In: $NEXI NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGAITHERSBURG, Md...
whytestocks - February 2, 2024

RE:NEXI....hard to keep on top of things....

the previous one was for raising upto 50M, today it is a direct offering where they offered unregistered warrants which will bring the...
Iseneschal - February 2, 2024

NEXI....hard to keep on top of things....

The 8K is about terminating an old agreement date June 2022 between Cantor and Nexi to raise upto 50 M cash , so the company is not...
Iseneschal - February 2, 2024

RE:NEXI....The P.O is terminated

Inline XBRL Viewer (sec.gov)
Iseneschal - February 2, 2024
View more Bullboard ››

Innocan Pharma Corp

Innocan Pharma Corp

Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the ...
View More »